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Abstract
Objective. To assess the inter-rater reliability of the BILAG2004-Pregnancy index for assessment of SLE
disease activity in pregnancy.
Methods. Pregnant SLE patients were recruited from four centres and assessed separately by two raters/
physicians in routine clinical practice. Disease activity was determined using the BILAG2004-Pregnancy
index. Reliability was assessed using level of agreement, k-statistics and analysis of disagreement. Major
disagreement was defined as a score difference of A and C/D/E or B and D/E between the two raters, and
minor disagreement was a score difference of A and B or B and C between raters.
Results. A total of 30 patients (63.3% Caucasian, 13.3% Afro-Caribbean, 16.7% South Asian) were
recruited. The majority of patients had low-level disease activity according to the local rater’s assessment,
and there was no grade A activity, with grade B activity present in the following systems: mucocutaneous
(nine patients), musculoskeletal (two patients), cardiorespiratory (one patient) and renal (one patient). The
distribution of disease activity was similar to the external rater’s assessment. Good levels of agreement
(>70%) were achieved in all systems. k-statistics were not appropriate for use in the gastrointestinal,
ophthalmic, constitutional and neuropsychiatric systems, as there was minimal variation between patients
but good levels of agreement otherwise. There were three major disagreements (0.1 per patient, all
differences between B and D/E) and five minor disagreements (0.17 per patient).
Conclusion. The BILAG2004-Pregnancy index is reliable for assessment of disease activity in pregnant
SLE patients.
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Introduction
SLE is a complex multi-system autoimmune disease that
predominantly affects women of child-bearing age. With
improved management and survival of SLE patients, more
patients with SLE are getting pregnant. The assessment of
SLE disease activity is made more challenging during
pregnancy, as many pathophysiological changes in preg-
nancy may be confused with manifestations of SLE dis-
ease activity.
The BILAG-2004 index is a system-based disease
activity measure that has been validated for use in SLE
outside of pregnancy [13]. It is one of the preferred
disease activity outcome measures used in clinical studies
of SLE [4]. Therefore, there is a need to develop a
system-based disease activity measure for use in preg-
nancy to ensure continuity of assessments when patients
become pregnant in long-term longitudinal studies of SLE,
which use the BILAG-2004 index as the disease activity
outcome measure. Furthermore, consistent use of a stan-
dardized and validated disease activity outcome measure
in the assessment of pregnant SLE patients may help
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address the conflicting reports of the effects of pregnancy
on exacerbation of SLE disease activity.
In developing an index for use in pregnancy that is
based on the BILAG-2004 index, we have made modifi-
cations to account for pathophysiological changes in
pregnancy. Generally it retains similarity to the BILAG-
2004 index, with the biggest change in the scoring of
the renal system, whereby changes in levels of
anti-dsDNA and complement (C3 and C4) influence the
scoring owing to proteinuria from LN. Otherwise the
other changes are mainly in the glossary and definition
of items to emphasize to physicians using the index to
be aware of pathophysiological changes in pregnancy
that might be confused with SLE activity. We have re-
tained the nine systems and the scoring scheme of the
BILAG-2004 index, which allows for seamless transition of
assessment from the pregnant to the non-pregnant state.
This modified index is known as the BILAG2004-
Pregnancy index (BILAG2004-P), which comprises the
BILAG2004- Pregnancy index form, glossary and scoring
(see supplementary data available at Rheumatology
Online). This cross-sectional study was designed to
assess the inter-rater reliability of the BILAG2004-
Pregnancy index in assessment of SLE disease activity
in pregnancy.
Methods
This was a multicentre cross-sectional study involving four
centres across the UK. Pregnant SLE patients, who satis-
fied the revised ACR criteria for classification of SLE, were
recruited [5, 6]. Patients were excluded from the study if
they were younger than 18 years or unable to provide valid
consent. This study received ethical approval from Trent
Research Ethics Committee and local research and
development approval from all participating centres
(Birmingham Womens’ Hospital, University College
London Hospitals, St Thomas’ Hospital and Sheffield
Teaching Hospitals). This study was carried out in accord-
ance with the Declaration of Helsinki, and written consent
was obtained from patients.
Patients were assessed independently by two phys-
icians separately, a local rheumatologist/rater and an
external rheumatologist/rater (C.-S.Y.). This study was
performed in the setting of routine practice, and medical
records were available to both raters. The local and
external raters were not aware of the outcome of each
other’s assessment until after completion of the study.
Disease activity was determined using the BILAG2004-
Pregnancy index. Following the study at each centre
there was discussion between the raters on the differ-
ences in scoring between them and on issues related to
the face and content validity of the index.
Statistical analysis
All statistical analyses were performed with Stata for
Windows version 8 (Stata Corp., College Station, TX,
USA). For this analysis, BILAG2004-Pregnancy index
scores of D and E were combined, as they both indicate
inactivity. Inter-rater reliability of the index was assessed
using level of agreement between raters, k-statistics and
analysis of disagreement in scores between raters.
For each system in the index, the percentage of assess-
ments on which both raters agreed was calculated. As
k-statistics perform poorly when there is little variation
within the population, they are only used where appropri-
ate (when there is sufficient variation in scores between
patients). k-statistics are based on a simple two-way
tabulation of external rater vs local rater scores [7, 8].
Both unweighted and weighted level of agreement and
k-statistics were calculated. The weighting used to calcu-
late the weighted level of agreement and k-statistics re-
flects our clinical judgement of the severity of the possible
disagreements (Supplementary Table A, available as sup-
plementary data at Rheumatology Online). CIs were cal-
culated for k-statistics, and as the scoring for each
system has more than two categories, a bootstrap tech-
nique with 1000 replications was used.
Analysis of disagreement calculates the number of dis-
agreements in scores between raters. Disagreement is
classified as major disagreement or minor disagreement.
The scores can be broadly divided into high-level activity,
as represented by A (severe activity) and B (moderate
activity) scores that are generally treated, and low-level
activity, as represented by C (mild activity) and D/E
(inactivity) scores that are usually not treated (treatment
may actually be reduced). Therefore major disagreement
is defined as the difference between high-level and low-
level activity between the two raters (score difference of A
and C/D/E or B and D/E), and minor disagreement is
defined as a single-level difference in the level of activity
between raters (score difference of A and B or B and C).
Score difference of C and D/E is not included, as it is
considered to be of little clinical significance.
Results
A total of 30 patients were recruited with a mean age of
30.3 years (S.D. 5.0 years), mean disease duration of 5.7
years (S.D. 4.0 years) and mean gestation of 21.8 weeks
(S.D. 7.1 weeks). The ethnic distribution was 63.3%
Caucasian, 13.3% Afro-Caribbean, 16.7% South Asian
and 7.7% others. Based on the local rater’s assessment,
the majority of patients had low-level disease activity
(grades C, D or E), and there was no grade A activity in
any patient, with grade B activity present in the follow-
ing systems: mucocutaneous (nine patients), musculo-
skeletal (two patients), cardiorespiratory (one patient)
and renal (one patient). The distribution was similar
using the external rater’s assessment: 2 grade A activity
(mucocutaneous 1, renal 1) and 10 grade B activity
(mucocutaneous 8, musculoskeletal 2).
The two-way tabulation of the local rater’s scores
against the external rater’s scores for five systems,
where there was sufficient variation in scores among pa-
tients, is shown in Table 1. There was absence of disease
activity in gastrointestinal and ophthalmic systems in all
patients as assessed by both raters (perfect agreement).
Similarly, there was clustering of inactivity in constitutional
and neuropsychiatric systems with difference in scores
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between the raters of C and D in one patient for each
system.
The level of agreement (unweighted and weighted) and
k-statistics (unweighted and weighted) for each system
are shown in Table 2. There was good level of agreement
(weighted agreement>70%) in all the systems. There
were good weighted k-statistics (>0.40) in muco-
cutaneous, musculoskeletal, cardiorespiratory, renal and
haematological systems. k-statistics were not appropriate
for use in the constitutional, neuropsychiatric, gastrointes-
tinal and ophthalmic systems, as there was very little vari-
ation in scores between patients.
There were few disagreements in scores between raters
in this study, with three major disagreements (0.10 per
patient, all of which were differences in score between B
and D/E) and five minor disagreements (0.17 per patient).
The major disagreements were in the mucocutaneous
(one), cardiorespiratory (one) and renal (one) systems,
whereas the minor disagreements were in the muco-
cutaneous (one difference in score of A and B, one differ-
ence in score of B and C), musculoskeletal (two
differences in score of B and C) and renal (one difference
in score of A and B) systems.
Discussion
This study has demonstrated that the BILAG2004-
Pregnancy index is reliable for assessment of disease ac-
tivity in a representative sample of pregnant SLE women.
This index is based on the BILAG-2004 index with modi-
fications to take into account pathophysiological changes
of pregnancy.
The majority of the changes were in the glossary, which
reminds the physician to differentiate disease activity from
pregnancy-related pathophysiological changes such as
transient facial blush, melasma/chloasma, bland effusion
of knees, mechanical hip/knee pain, pre-eclampsia/
eclampsia, haemodilution of pregnancy and HELLP syn-
drome. The most significant change is in the scoring of the
renal system, whereby changes in the anti-dsDNA or
complement levels are taken into consideration in the
scoring of proteinuria due to SLE disease activity.
Furthermore, rising blood pressure is no longer con-
sidered to be due to SLE activity, and it has no bearing
in the scoring for the renal system. The main reason for
inclusion of serological markers is the difficulty in differ-
entiating proteinuria of pre-eclampsia from LN in the
TABLE 1 Two-way tabulation of local rater scores against external rater scores for mucocutaneous, musculoskeletal,
cardiorespiratory, renal and haematological systems
External rater’s system score
Mucocutaneous Musculoskeletal Cardiorespiratory Renal Haematological
A B C D A B C D A B C D A B C D A B C D
Local rater’s
system score
A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
B 1 7 0 1 0 1 1 0 0 0 0 1 1 0 0 0 0 0 0 0
C 0 1 1 1 0 1 5 4 0 0 1 0 0 0 0 0 0 0 9 0
D 0 0 3 15 0 0 1 17 0 0 0 28 0 1 0 28 0 0 2 19
Bold values represent perfect agreement between raters.
TABLE 2 Level of agreement and k-statistics for the BILAG2004-Pregnancy index
Systems Agreement, % (weighted) i (95% CI) Weighted i (95% CI)
Constitutional 96.7 (98.3) NA NA
Mucocutaneous 76.7 (87.5) 0.59 (0.35, 0.85) 0.73 (0.48, 0.88)
Neuropsychiatric 96.7 (98.3) NA NA
Musculoskeletal 76.7 (88.3) 0.53 (0.27, 0.81) 0.60 (0.31, 0.80)
Cardiorespiratory 96.7 (96.7) 0.66 (0, 1) 0.48 (0.31, 0.77)
Gastrointestinal 100 (100) NA NA
Ophthalmic 100 (100) NA NA
Renal 93.3 (95.8) 0.31 (0, 0.49) 0.57 (0.32, 0.87)
Haematological 93.3 (96.7) 0.85 (0.60, 1) 0.85 (0.60, 1)
NA: k-statistics not appropriate for use in these systems.
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absence of active urinary sediments. In the context of
rising anti-dsDNA levels and/or decreasing complement
C3/C4 levels, proteinuria is more likely due to LN, and
hence the additional weighting in the scoring of proteinuria
that is provided by serological markers. However, the
changes in anti-dsDNA and/or complement levels on
their own have no bearing on the scoring of the index. In
addition, the scoring thresholds for plasma creatinine and
haemoglobin level (in grades B and C) have been adjusted
to reflect the effect of haemodilution from pregnancy.
The reliability of this index was assessed using several
measures in similar fashion to the reliability study of the
BILAG-2004 index [1]. However, few patients recruited to
this study had active disease, and those who did have
active disease typically had only grade B score and
none had grade A activity as assessed by both raters.
This is in keeping with other recent studies of SLE disease
activity in pregnancy and reflects current management of
pregnant SLE patients, which starts preconception. SLE
patients are advised to get pregnant after the disease is
quiescent for at least 6 months to minimize the risk of
flare of disease during pregnancy. Furthermore, pregnant
SLE patients are monitored closely and any evidence of
active disease will be treated early to reduce the extent of
disease activity flare. Therefore current management
strategies of SLE patients are designed to reduce the
likelihood of active disease occurring in pregnancy. As
such, we found clustering of patients with no activity in
constitutional, neuropsychiatric, gastrointestinal and
ophthalmic systems. As a result, k-statistics were not
useful in the assessment of reliability in this study, and
there were a small number of disagreements in scores
between raters.
A potential limitation of this study is that the index has
not been tested through its entire range of possible dis-
ease activity. No major issue was identified with regards
to the face and content validity of this index in this study.
Therefore, as the BILAG2004-Pregnancy index is very
similar to the BILAG-2004 index, which has been compre-
hensively validated, we are confident that this index is
suitable for use to assess disease activity in pregnant
SLE patients. Further validation of this index with regards
to construct/criterion validity and sensitivity to change is
required.
Rheumatology key message
. The BILAG2004-Pregnancy index is reliable for as-
sessment of SLE disease activity in pregnancy.
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